mlcon 1.0 mlcon 2.0

Data integration and AI mining of pooled drug-CRISPR screens identifies novel targets and resistance to cancer treatments

Dimitris Polychronopoulos, Associate Director, Oncology Bioinformatics and Data Science, AstraZeneca
Miika Ahdesmaki, Director, Early Computational Oncology, AstraZeneca
Speakers:
Dimitris Polychronopoulos, Associate Director, Oncology Bioinformatics and Data Science, AstraZeneca
Miika Ahdesmaki, Director, Early Computational Oncology, AstraZeneca

AstraZeneca-CRUK Functional Genomics Centre’s (FGC) vision is to accelerate the development of new treatments for people with cancer. The FGC generates pooled drug-CRISPR screen data for uncovering novel targets to battle resistance to cancer therapies. This talks focuses on our FAIR data strategy, integration of drug-CRISPR data with other large scale pre/clinical data sets and AI mining approaches to triage the pooled drug-CRISPR hits with a clear impact on oncology new target strategy.